VXRT Vaxart

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Conference call to begin at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.

The conference call can be accessed using the following information:

Webcast:

Date: Tuesday, May 13, 2025 – 4:30 p.m. ET

Domestic: (877) 407-0832

International: (201) 689-8433

Conference ID: 13753354

Investors may submit written questions in advance of the conference call to by May 12, 2025.

A replay of the webcast will be available on the Company’s website at following the conclusion of the event.

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor Relations:

Matt Steinberg

FINN Partners  



(646) 871-8481

This press release was published by a CLEAR® Verified individual.



EN
02/05/2025

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host First Quarter 2025 Business Update and Financial Result...

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13 Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webc...

May 2, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Present at the Citizens Life Sciences Conference

Vaxart to Present at the Citizens Life Sciences Conference SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that members of the management team will present at the Citizens Life Sciences conference taking place May 7-8, 2025. Presentation Details:Date and Time: Wednesday, May 7 at 1:00 PM ETWebcast: A live webcast will be available on the Company’s website at , and a replay of the presentation will be available for 30 days following the conclusion of the event. Institutional investors interested in meeting with management duri...

April 30, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pi...

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate - Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs. “Completing enrollment in this trial bring us one step closer in our development of a norovirus vaccine, where there is a significant unmet need,” said Steven Lo, Chief Exe...

April 30, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23 SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Washington 2025 in Washington, D.C. on Wednesday, April 23, 2025. The Company has appeared repeatedly at the annual event in Washington, D.C. Presentation Information: Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral ta...

April 16, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(...

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the Board of Directors granted inducement equity awards to (i) seven new non-executive employees, covering an aggregate of 292,500 shares of its common stock, consisting of stock options to purchase 195,000 shares and restricted stock unit awards covering 97,500 shares, and (ii) Laurie Hastings, our recently-appointed Senior Vice President, H...

March 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch